OTR Acquisition Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Woburn, mass.--(business wire)--comera life sciences holdings, inc. (“comera” or the “company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with otr acquisition corp. (nasdaq: otrau, otra and otraw) (referred herein as “otr”), a publicly traded special purpose acquisition company (spac). comera life sciences holdings, inc., the resulting combined company, will commence trading on the nasdaq capital market under the symbol “cmra” on may 20, 2022. otr’s shareholders approved the transaction on may 10, 2022. the transaction was previously approved by comera’s shareholders...

Woburn, mass.--(business wire)--comera life sciences, inc. (“comera” or the “company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas. under the terms of the agreement, comera will utilize its proprietary sqore™ formulation platform to develop a subcutaneous formulation of the partner’s currently marketed medicine. “our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma companies and leverage our sqore platform to develop subcutaneous formulations to improve access and patient use for much-needed medications,” said jeff hackman, chief executive officer and chairman of comera...

Woburn, mass.--(business wire)--comera life sciences, inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that robert p. mahoney, ph.d., chief scientific officer, will present at the pegs boston conference & expo, being held may 2-6, 2022, in-person. dr. mahoney will discuss comera’s lead, patented caffeine-based excipient, which significantly reduced the viscosity of prominent monoclonal antibodies without affecting their stability or biologic activity in a recent peer-reviewed study.1 the presentation details are as follows: title: viscosity reducing excipients for highly concentrated antibody formulations time: may 4, 2022, 1:00 – 1:30 pm et location: room 302, hynes convention center, boston description: patients would rather have a subcutaneous injection than an iv infusion, so biologics are often formulated at high concentration to enable self-administration in a small volume...

Woburn, mass. & ahmedabad, india--(business wire)--today, comera life sciences, inc. (“comera” or the “company”) and intas pharmaceuticals ltd. (“intas”) announced a research collaboration to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. under the terms of the partnership agreement, comera will develop a differentiated formulation of an intas product using comera’s innovative proprietary sqore™ formulation platform. intas will initially provide research funding with the option to acquire global rights to the formulation through an exclusive license with responsibility for subsequent development and commercialization...

Woburn, mass. & miami--(business wire)--comera life sciences, inc. (“comera”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and otr acquisition corp. (nasdaq: otra) (“otr”), a publicly traded special purpose acquisition company (spac), today announced that the securities and exchange commission (“sec”) has declared the registration statement on form s-4 filed in connection with the proposed business combination between the two companies, to be effective. a special meeting of otr stockholders (the "special meeting") to approve, among other things, the proposed business combination, will be held in virtual format on may 10, 2022 at 2:00 p...

The shares of OTR Acquisition are climbing after the SPAC's shareholders overwhelmingly approved a merger with Comera. The post Why Is OTR Acquisition (OTRA) Stock Up Today?